Abstract: Provided is a method of administering a virus to tumor tissues using an endoscope. A method of administering a virus to tumor tissues using an endoscope, which is characterized in that it comprises inserting an endoscopic puncture needle filled with a virus-containing solution into tumor tissues and injecting the virus into the tumor tissues.

Abstract: [Problem] An ester compound having low viscosity, excellent fluidity even at low temperatures, and a high viscosity index; and a lubricating oil base oil containing said compound are provided. [Solution] The present invention provides an ester compound indicated by formula (I). Formula (I) (in formula (I), R1 is a hydrocarbon group having 1 to 35 carbon atoms and at least one hydrogen in the hydrocarbon group may be independently substituted with a group indicated by formula (II)). Formula (II) (in formula (II), R2 is a linear alkyl having 1 to 30 carbon atoms or a branched alkyl having 3 to 30 carbon atoms.

Abstract: [Problem] An ester compound having low viscosity, excellent fluidity even at low temperatures, and a high viscosity index; and a lubricating oil base oil containing said compound are provided. [Solution] The present invention provides an ester compound indicated by formula (I). Formula (I) (in formula (I), R1 is a hydrocarbon group having 1 to 35 carbon atoms and at least one hydrogen in the hydrocarbon group may be independently substituted with a group indicated by formula (II)). Formula (II) (in formula (II), R2 is a linear alkyl having 1 to 30 carbon atoms or a branched alkyl having 3 to 30 carbon atoms.

Abstract: A pair of main molds forming an outer peripheral face of a piston and a pair of side cores forming the pair of cutout recess parts of the piston are prepared, the main mold and the side core are set so as to form a cavity corresponding to the piston, the cavity is charged with molten metal, and when the side core is moved downward and in a direction away from the central axis of the piston so as to carry out mold release from the cutout recess part after the piston within the cavity has solidified, the side core is tilted in a direction in which an upper end thereof approaches the central axis of the piston. Thus, it is possible to release a core smoothly from a cutout recess part without it biting into an inside face of the cutout recess part.

Abstract: A pair of main molds forming an outer peripheral face of a piston and a pair of side cores forming the pair of cutout recess parts of the piston are prepared, the main mold and the side core are set so as to form a cavity corresponding to the piston, the cavity is charged with molten metal, and when the side core is moved downward and in a direction away from the central axis of the piston so as to carry out mold release from the cutout recess part after the piston within the cavity has solidified, the side core is tilted in a direction in which an upper end thereof approaches the central axis of the piston. Thus, it is possible to release a core smoothly from a cutout recess part without it biting into an inside face of the cutout recess part.

Abstract: This invention provides a therapeutic agent for hepatitis C comprising, as an active ingredient, a compound having anti-HCV activity useful in treatment of hepatitis C. The therapeutic agent for hepatitis C comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: An aldehyde derivative represented by the general formula (2) is reacted with ketene in the presence of a Lewis acid catalyst to produce a novel 2-oxetanone derivative (1), which is then purified to a 2-oxetanone derivative having a high trans-isomer purity, and then converted to a vinyl derivative (3) through decarboxylation reaction.

Abstract: An aldehyde derivative represented by the general formula (2) is reacted with ketene in the presence of a Lewis acid catalyst to produce a novel 2-oxetanone derivative (1), which is then purified to a 2-oxetanone derivative having a high trans-isomer purity, and then converted to a vinyl derivative (3) through decarboxylation reaction.

Abstract: The present invention relates to pyrimidine compounds and their use as pharmacologically active agents capable of suppressing and inhibiting viruses (e.g., oncolytic viruses). The subject compounds and compositions are particularly useful in treating and suppressing human oncolytic adenovirus infection.

Abstract: The invention is directed to a method of increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate by administration of a therapeutically effective amount of the drug with food. The invention also provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and a pharmaceutically acceptable carrier, prescribing information, and a container, wherein the prescribing information includes advice to a patient regarding administration of the drug with food to improve bioavailability.

Abstract: The invention is directed to a method of increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate by administration of a therapeutically effective amount of the drug with food. The invention also provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and a pharmaceutically acceptable carrier, prescribing information, and a container, wherein the prescribing information includes advice to a patient regarding administration of the drug with food to improve bioavailability.

Abstract: Optically active 1-substituted phenyl-2-nitro alcohol derivatives having the formula (1) and the process for producing thereof, and 1-substituted phenyl-2-amino alcohol derivatives having the formula (2) and the process for producing thereof from the optically active 1-substituted phenyl-2-nitro alcohol derivatives. From these nitro alcohols, pharmaceuticals such as (R)-albutamin and (R)-sarmeterol useful as a bronchodilator is obtained via optically active amino alcohols which are useful pharmaceutical intermediates.

Abstract: Optically active 1-substituted phenyl-2-nitro alcohol derivatives having the formula (1) and the process for producing thereof, and 1-substituted phenyl-2-amino alcohol derivatives having the formula (2) and the process for producing thereof from the optically active 1-substituted phenyl-2-nitro alcohol derivatives. From these nitro alcohols, pharmaceuticals such as (R)-albutamin and (R)-sarmeterol useful as a bronchodilator is obtained via optically active amino alcohols which are useful pharmaceutical intermediates.

Abstract: Optically active 1-substituted phenyl-2-nitro alcohol derivatives having the formula (1) and the process for producing thereof, and 1-substituted phenyl-2-amino alcohol derivatives having the formula (2) and the process for producing thereof from the optically active 1-substituted phenyl-2-nitro alcohol derivatives. From these nitro alcohols, pharmaceuticals such as (R)-albutamin and (R)-sarmeterol useful as a bronchodilator is obtained via optically active amino alcohols which are useful pharmaceutical intermediates.

Abstract: The invention provides a combination comprising (a) S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate or prodrug of the active form thereof, and (b) at least one HMG CoA reductase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for treatment and prophylaxis of a cardiovascular disorder involving the use of the aforementioned active ingredients.

Abstract: The invention is directed to a method of increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate by administration of a therapeutically effective amount of the drug with food. The invention also provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and a pharmaceutically acceptable carrier, prescribing information, and a container, wherein the prescribing information includes advice to a patient regarding administration of the drug with food to improve bioavailability.

Abstract: Optically active 1-substituted phenyl-2-nitro alcohol derivatives having the formula (1) and the process for producing thereof, and 1-substituted phenyl-2-amino alcohol derivatives having the formula (2) and the process for producing thereof from the optically active 1-substituted phenyl-2-nitro alcohol derivatives. From these nitro alcohols, pharmaceuticals such as (R)-albutamin and (R)-sarmeterol useful as a bronchodilator is obtained via optically active amino alcohols which are useful pharmaceutical intermediates.

Abstract: Optically active 1-substituted phenyl-2-nitro alcohol derivatives having the formula (1) 1

Abstract: A method for activating cholinesterase, comprising administering a compound having a prolyl endopeptidase inhibitory activity to treat cocainism, is disclosed.

Abstract: A production process with good efficiency, and applicable to production of a synthetic intermediate of a new quinolone anti-fungus agent CP-99219, is provided.A production process of an intermediate of a new quinolone compound expressed by the formula (IV) ##STR1## wherein R.sup.3 represents a benzyl group, a diphenylmethyl group, etc. and R.sup.4 represents a linear or branched alkyl group of 1 to 8C, a cycloalkyl group, etc.which process employs as a starting substance, a cyclopropanetricarboxylic acid triester expressed by the formula (I) ##STR2## wherein R.sup.1 and R.sup.2 represent a linear or branched alkyl group, a cycloalkyl group, an aryl group or an aralkyl group,and passes through seven steps.